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Antibacterial Activity of 
Specialized Biomolecules
Introduction
Bacterial growth can be inhibited by antimicrobial agents, causing
disruption of vital cellular functions resulting in rapid cell death.
Typically, these agents act at the level of the bacterial membrane, which
is a crucial structure for cell survival. Currently, there is a vast array of
antimicrobial biomolecules. For many years, the most widely used have
been the antibiotics. However, their excessive consumption has led to
an alarmingly high resistance development by bacterial pathogens,
raising a serious global public-health problem. Hence, the interest in the
research for novel alternatives to antibiotics has been growing. Natural
products are becoming very promising as antimicrobial agents, being
considered safe and environmentally friendly. Here, we envisage the
evaluation of the antimicrobial efficacy of antimicrobial peptides (AMPs),
namely LL37 and pexiganan, and essential oils (EOs), tea tree oil
(TTO), cinnamon leaf oil (CLO) and niaouli oil (NO), against four
bacteria commonly associated to nosocomial infections:
Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli
and Pseudomonas aeruginosa. The antibiotic vancomycin and silver




1) Agar-Well Diffusion Assay
Initial Bacteria Concentration: 2x106 CFUs/mL in TSB
For the agents, the highest concentration was used.
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AgNPs Distilled water (dH2O) 5000-1.95 µg/mL
Vancomycin dH2O 2000-1.95 µg/mL
LL37 Phosphate buffered saline solution (PBS) 1000-0.98 µg/mL
Pexiganan dH2O 1000-0.98 µg/mL
TTO Mueller Hinton broth (MHB) 500-0.18 mg/mL
CLO MHB 500-0.18 mg/mL
NO MHB 500-0.18 mg/mL
2) Minimum Inhibitory Concentrations (MICs)




S. aureus S. epidermidis E. coli P. aeruginosa
AgNPs
11.5 ± 1.7 10.6 ± 0.6 8.8 ± 0.5 8.8 ± 3.0
Vancomycin
22.5 ± 0.5 22.5 ± 0.5 8.0 ± 0.1 8.0 ± 0.2
LL37
6.5 ± 0.1 6.5 ± 0.5 6.3 ± 0.1 6.2 ± 0.1
Pexiganan
9.0 ± 0.5 12.2 ± 0.6 8.0 ± 1.5 12.0 ± 0.1
TTO
20.2 ± 0.1 15.0 ± 0.5 15.5 ± 0.5 13.3 ± 0.3
CLO
21.5 ± 0.5 15.0 ± 1.0 15.0 ± 1.9 15.0 ± 0.6
NO




S. aureus S. epidermidis E. coli P. aeruginosa
AgNPs 4000.0 µg/mL 4000.0 µg/mL 4000.0 µg/mL 1250.0 µg/mL
Vancomycin 7.8 µg/mL 7.8 µg/mL 1000.0 µg/mL 1000.0 µg/mL
LL37 500.0 µg/mL 500.0 µg/mL 125.0 µg/mL 250.0 µg/mL
Pexiganan 31.3 µg/mL 7.8 µg/mL 62.5 µg/mL 31.3 µg/mL
TTO 67.1 mg/mL 179.0 mg/mL 33.6 mg/mL 268.5 mg/mL
CLO 26.2 mg/mL 26.2 mg/mL 19.7 mg/mL 39.3 mg/mL
NO 137.0 mg/mL 182.6 mg/mL 137.0 mg/mL 365.2 mg/mL
3) Kill-time Analysis: Bacteria Viability
Initial Bacteria Concentration: 2x107 CFUs/mL in MHB
For the agents, the MIC value was used.
4) Cell-Wall Disruption: Mechanisms of Action (SEM observations)
Initial Bacteria Concentration: 2x107 CFUs/mL in MHB
For the agents, the MIC value was used.
Conclusions:  All agents were effective against the selected bacteria. 
Interestingly, the AgNPs required a higher concentration (4000–1250 
µg/mL) to induce the same effects as the AMPs (500–7.8 µg/mL). 
Pexiganan was the most effective biomolecule. 
For more details please refer to DOI: 10.3390/antibiotics9060314 
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